Diamyd Medical AB (publ) (DMYD.B)

Nasdaq First North Growth Market | Biotech | Precision medicine for diabetes
Free
No email, no account, no signup.
Pulling latest news for Diamyd Medical AB (publ)…
Bull
Bear
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Order analysis – $4.99
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
Nasdaq First North Growth Market
Type
Biotech
Sector
Precision medicine for diabetes
Market Cap
$21M
We're already tracking Diamyd Medical AB (publ) — here are the latest events we've registered

Recent News

  • In April 2026, the company discontinued its Phase 3 DIAGNODE-3 trial following a negative interim analysis, leading to a strategic review and the resignation of CEO Ulf Hannelius. On May 5, 2026, the company reported positive regulatory feedback regarding its biomanufacturing facility in Umeå.
Want to know how this news affects Diamyd Medical AB (publ)? Order the analysis.
Order analysis – $4.99

What you get

A complete express analysis — not just a signal. Delivered as a webpage in your account.

  • Signal: BUY / HOLD / SELL — with clear reasoning
  • Sentiment score 1–10 based on news, reports, and market data
  • Risk score 1–10 (dilution, jurisdiction, execution)
  • Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
  • Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
  • Upcoming catalysts with dates
  • Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Diamyd Medical AB (publ) will be delivered in the same format.
Order analysis – $4.99
Not satisfied? Get your money back within 7 days — no questions asked.
Diamyd Medical AB (publ) (DMYD.B)
Fresh analysis on demand
Order analysis – $4.99
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.